Navigation Links
US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
Date:8/16/2009

EAST HANOVER, N.J., Aug. 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.

Extavia is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with the disease as shown by magnetic resonance imaging (MRI)(4).

The same medicinal product as Betaseron(R)*, Extavia offers patients and physicians a new branded version of interferon beta-1b, a first-line disease-modifying therapy that has been a standard-of-care for MS in the US for more than 16 years(1). Extavia will be marketed by the Pharmaceuticals Division of Novartis.

"Interferon is a mainstay of treatment in MS," said Doug Jeffery, MD, Associate Professor at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, USA. "With the approval of Extavia, patients have another option with a well-established safety and efficacy profile to help manage this disease."

MS is estimated to affect approximately 400,000 patients in the US, of whom more than 80% have relapsing-remitting MS(5). MS is one of the most common causes of neurological disability in young adults. It is a chronic autoimmune disease in which the body's immune system attacks the myelin sheath, or protective tissue surrounding the nerve fibers that carry electrical signals in the brain(6). The destruction of myelin causes problems with muscle control and strength, vision, balance, sensation and mental function(7).

"Novartis has been a leader in neuroscience for more than 50 years, having pioneered a numb
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
2. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
3. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
4. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
5. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
6. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
7. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
8. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
9. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
10. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
11. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2012)... May 23, 2012 Medical Tactile, Inc. (MTI), ... Incorporated, today announced that they have developed a pre-commercial ... sensor technology for breast cancer screening.  ... Komen Foundation, 1.6 million women worldwide were diagnosed with ... the disease. Although early detection is the best means ...
(Date:5/23/2012)... Kraton Performance Polymers, Inc. (NYSE: "KRA"), ... or SBCs , and PolyOne Distribution, a ... and solutions, announce the execution of a distribution ... PolyOne product line. "Kraton Polymers ... IR products due to their deep knowledge about ...
(Date:5/23/2012)... 2012  Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical ... for its U.S. phase 2 clinical trial, T ... G reater E fficacy T rial ... in patients with non-tuberculous mycobacterial (NTM) lung disease. ... to support current NTM treatment recommendations, and no new ...
Breaking Medicine Technology:Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 2Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 3Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 4Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line 2Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 2Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 4Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 5Resource savvy communities generate healthy sustainable changes 15181 1Resource savvy communities generate healthy sustainable changes 15181 2Radiation Oncology Services of America Inc to Work With Washington University on Quality Assurance Initiative 10552 1Radiation Oncology Services of America Inc to Work With Washington University on Quality Assurance Initiative 10552 2U S Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014 10547 1U S Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014 10547 2
... Nektar,Therapeutics (Nasdaq: NKTR ) today ... study,for NKTR-118 (PEG-naloxol), an oral treatment being ... clinical manifestations of,opioid-induced bowel dysfunction (OBD). The ... safety and tolerability,of NKTR-118 in patients experiencing ...
... Data and Emerging Clinical Practice Experience Support ... HYLENEX Efficacy and ... Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and commercializing,products ... of the INFUSE-LR clinical trial results in the Journal,of Palliative ...
Other Medicine Technology:Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 2Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 3Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 4Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 5Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 2Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 3Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 5
(Date:5/23/2012)... proteins of the same kind, thereby triggering skeletal and ... researchers from the RUB Heart and Diabetes Center NRW ... in an interdisciplinary research project with colleagues from the ... the Journal of Biological Chemistry . , ... forms stabilizing filaments inside of the cells. Different mutations ...
(Date:5/23/2012)... FRANCISCO Prior treatment with inhaled corticosteroids in ... pneumonia (CAP) is associated with a lower incidence ... new study from researchers in Spain. , A ... (excess fluid that accumulates between the two pleural ... that arises as a result of a pneumonia, ...
(Date:5/22/2012)... Bend Research Inc., a leading independent ... expansion of its existing hot-melt extrusion (HME) ... Leistritz twin-screw mixer/extruder. , The 18mm ... 27mm Leistritz and 19mm Baker Perkins extruder ... high-shear wet-granulation capabilities. Many projects have been ...
(Date:5/22/2012)... The uproar that began last year when the U.S. ... longer offer regular prostate-cancer tests to healthy men continued ... report. Overall, they stuck to their guns, stating that ... cancer, the PSA test, causes more harm than good ... even dangerous, treatments. , But many people simply don,t ...
(Date:5/22/2012)... , , TUESDAY, May 22 (HealthDay News) -- Two preliminary ... both the detection and treatment of pancreatic cancer. ... said they have fashioned a vaccine that, in early ... attacking cancer cells. The team -- from Case ... Cancer Center at University Hospitals Case Medical Center in ...
Breaking Medicine News(10 mins):Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Long-term ICS use reduces pleural effusion in patients with CAP 2Health News:Psychological Science explains uproar over prostate-cancer screenings 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 3Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 4
... 18 Women,s, health and,environmental groups today called on ... wake of product tests released last week by the,Campaign ... an,independent lab, 61 percent (20 samples) contained detectable levels ... lipsticks with the highest lead,content were made by L,Oreal ...
... Decisions Network,(MDN) announces Food and Drug Administration 510(k) ... The MDN-CGS software is used,by hospital nurses to ... administered to patients with elevated levels of blood,glucose, ... to energy for survival. More and more ...
... to Reduce Number Denied by President, a Few in ... 2,000,children will join the ranks of the uninsured, adding ... public health insurance,according to new data released today by ... new analysis, American Families Face Harsh Reality: 2,000 Children,Join ...
... Mass., Oct. 18 Yankee Candle Company,Inc., the ... home fragrance, is,taking action in the fight against ... Logo: http://www.newscom.com/cgi-bin/prnh/20071018/NYTH093LOGO-b ) Yankee Candle ... breast,cancer awareness and research. The company is donating ...
... returning U.S. veterans , , THURSDAY, Oct. 18 (HealthDay News) ... when deciding how best to treat post-traumatic stress disorder ... of the data concludes. , The Institute of Medicine ... Affairs, which noted that about 12.6 percent of personnel ...
... Haas (NYSE:,ROH) announced today that it has ... used as a bonding alternative for pressure,sensitive ... like,door panels, interior pillars, instrument panels and ... before seen or thought possible,in an aqueous ...
Other Medicine News:Health News:Health Groups Call on Cosmetic Giant L'Oreal to Remove Lead From Lipstick 2Health News:FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software 2Health News:Families Face Harsh Reality: 2,000 Children Join the Uninsured Each Day 2Health News:Yankee Candle Company Sheds Some Light In The Fight Against Breast Cancer 2Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 2Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 3Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 4Health News:New Water-Based Acrylic Pressure-Sensitive Adhesive Defeats Heat and Humidity Issue 2
The CapSureFix line of pacing leads combines the benefits of steroid-eluting technology with screw-in active fixation, to allow long-lasting, low-threshold delivery of pacing therapies....
... Physique leads are small profile endocardial permanent ... With a lead body size of only ... of 7 F, the Physique lead is ... today. Available in both straight and pre-formed ...
Used with permanent pacing leads....
...
Medicine Products: